Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12612290 | 0.87 | BRD4 (0.37) | LMNAOPRM1SIGMAR1BRD4BRD2 | |
| SCHEMBL13003396 | 0.76 | — | — | |
| SCHEMBL18650812 | 0.74 | LMNA (0.30) | LMNA | |
| SCHEMBL17342257 | 0.72 | PIK3CD (0.39) | — | |
| SCHEMBL22511149 | 0.71 | SIGMAR1 (0.36) | SIGMAR1 | |
| SCHEMBL22450108 | 0.70 | KDM4E (0.32) | LMNA | |
| SCHEMBL22304568 | 0.70 | KDM4E (0.31) | LMNA | |
| SCHEMBL20551485 | 0.69 | KDM4E (0.30) | LMNA | |
| SCHEMBL22511151 | 0.67 | ALDH1A1 (0.39) | LMNA | |
| SCHEMBL22055778 | 0.67 | PIK3CD (0.46) | OPRM1SIGMAR1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023015199-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2017049068-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9382265-B2 | Oxazolidone compound, preparing method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20150361091-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1351/4885OPRM1 4045/4885SIGMAR1 3383/4885 |
| US-20150361091-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | CYP3A43, CYP2C9, F2 | LMNA 1739/4885OPRM1 9/4885SIGMAR1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.